Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis
Pooled result · All-cause death, DM populationResult — go to the resultRelative risk 0.81 95% CI 0.69–0.96Authors' conclusion
Our network meta-analysis revealed that empagliflozin users with diabetes experienced a lower risk of dying from any cause than those using dapagliflozin. Additionally, canagliflozin users demonstrated a reduced risk of cardiovascular death or HHF compared to dapagliflozin users in those without HF. In HF patients, less selective SGLT2 inhibitors showed superior CV composite outcomes, even surpassing the performance of highly selective SGLT2 inhibitors.
Study context
- Population
- Patients with and without comorbidities including diabetes mellitus (DM), heart failure (HF) and chronic kidney disease (CKD) in RCTs up to March 28, 2023
- Participants
- 75,334 patients14 RCTs
- Comparison
- Individual SGLT2i vs each other; highly vs less selective SGLT2i
- Outcome
- All-cause death, DM population
Methodological detailsrandom-effects model, Risk of Bias tool 2.0, CINeMA certainty of evidence, subgroup analysis by SGLT2i selectivity, Searched PubMed, Embase, Cochrane and ClinicalTrials.gov, 40,956 took SGLT2i and 34,378 did not
- Random-effects model
- Risk of Bias tool 2.0
- CINeMA certainty of evidence
- Subgroup analysis by SGLT2i selectivity
- Searched PubMed, Embase, Cochrane and ClinicalTrials.gov
- 40,956 took SGLT2i and 34,378 did not
Pooled result
As reported in the abstract
Relative risk
0.81
95% CI 0.69–0.96
Empagliflozinvs Dapagliflozin
RR 0.81 (95% CI 0.69–0.96)
Further pooled results
| Outcome | RR (95% CI) | |
|---|---|---|
| CV death or HHF, HF populationSotagliflozinvs DapagliflozinBorderline significantly lower risk with sotagliflozin | 0.90 (0.80–1.01) | |
| CV death or HHF, non-HF populationCanagliflozinvs Dapagliflozin | 0.75 (0.58–0.98) | |
| MACE, HF patientsLess selective SGLT2 inhibitorsvs Highly selective SGLT2 inhibitorsSubgroup analysis | 0.75 (0.62–0.90) | |
| 0.512Relative risk (log scale) |
Original publication
Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis. Cardiovasc Diabetol. Published 27 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →